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Minimal residual disease (MRD) following B-lymphoblastic leukemia (B-ALL) treatment 
has gained prognostic importance. Clonal immunoglobulin heavy chain (IGH) gene rear-
rangement is a useful follow-up marker in B-ALL owing to its high positivity rate. We evalu-
ated the performance and clinical applicability of a next-generation sequencing (NGS) as-
say for IGH rearrangement in B-ALL MRD monitoring. IGH rearrangement was tested by 
using fluorescence PCR-fragment analysis and the NGS assay in eight B-ALL patients. 
The NGS assay was run on two platforms: the Ion Torrent PGM (Thermo Fisher Scientific, 
USA) (18 samples from 1st to 7th patients) and the MiSeq system (Illumina, USA) (four 
samples from 8th patient). All initial diagnostic samples and four follow-up samples were 
positive for clonal IGH rearrangement with fluorescence PCR-fragment analysis and the 
NGS assay, and six follow-up samples were positive only with NGS. In one case with BCR-
ABL1 translocation, BCR-ABL1 quantitative PCR was negative but the NGS IGH assay 
was positive just prior to full-blown relapse, suggesting the high sensitivity and clinical util-
ity of the NGS assay. The NGS assay is proposed for MRD monitoring in B-ALL Additional 
studies are needed to confirm the clinical implications of cases showing positive results 
only in NGS. 
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The presence of minimal residual disease (MRD) after chemo-
therapy or bone marrow transplantation has been an important 
prognostic factor in B-lymphoblastic leukemia (B-ALL) [1, 2]. 
Conventionally, MRD can be detected by using multi-color flow 
cytometry or real-time PCR with high sensitivity. However, the 
detection of MRD can be limited in a subset of patients that lack 
leukemia-specific cell markers or harbor genetic abnormalities 
[1, 3]. 
In the early stage of B-cell differentiation, the immunoglobulin 
gene cluster regions undergo a complex rearrangement process 
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to produce diverse antibody-coding sequences [4]. When the 
immunoglobulin gene cluster regions are amplified by using spe-
cific primers, normal polyclonal cells show amplicons with vari-
able sizes reflecting the broad antibody repertoire, whereas tu-
mor cells derived from a single clone show amplicons with one 
or a few fixed sizes [5]. Therefore, clonal immunoglobulin gene 
rearrangement can be a useful diagnostic and monitoring marker 
in a broad range of B-cell lymphoproliferative neoplasms, includ-
ing B-ALL, plasma cell myeloma, and mature B-cell lymphoma 
[6-8]. However, conventional fluorescent PCR and fragment anal-
ysis have drawbacks, including difficulty in interpretation of peak 
patterns in some cases and relatively low sensitivity compared 
with other highly sensitive assays [9]. 
Rapid progression in next-generation sequencing (NGS) tech-
nologies has enabled highly sensitive cancer genomic testing in 
clinical laboratories [10]. Although some NGS-based clonal im-
munoglobulin heavy chain gene (IGH) rearrangement assays 
have already been tried for MRD monitoring of B-ALLs [6, 11], 
a considerable need still remains for a standardized IGH clonal-
ity testing with acceptable performance and streamlined work-
flow suitable to clinical laboratory. LymphoTrack IGH Assay (In-
VivoScribe Technologies, San Diego, CA, USA) includes a primer 
set targeting IGH loci for preparing multiplex PCR library prepa-
ration and can be used on two NGS platforms: Ion Torrent Per-
sonal Genome Machine (PGM; Thermo Fisher Scientific, Waltham, 
MA, USA) and the MiSeq system (Illumina, San Diego, CA, USA). 
We further validated the clinical utility of NGS for IGH rearrange-
ment in a clinical setting, using amplicon-based library prepara-
tion kit and two NGS platforms: Ion Torrent PGM (for 1st-7th pa-
tients) and the MiSeq system (for 8th patient).
Written informed consent was obtained from the patients’ par-
ents, according to the ethical guidance of the institutional review 
board of the Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea. Genomic DNA was extracted from bone 
marrow samples by using the QIAamp DNA Blood Mini Kit (Qia-
gen, Venlo, The Netherlands). 
PCR amplification for fragment analysis was performed by us-
ing the IdentiClone IGH Gene Clonality Assay kit (InVivoScribe 
Technologies). Multiplex primer sets in five master mixes target 
the variable, joining, and diversity region of the IGH locus. Frag-
ment detection and analysis was performed by using 3130 DNA 
Analyzer (Applied Biosystems, Foster City, CA, USA) and Gene-
Mapper 3.2 software (Applied Biosystems). Interpretation of clonal 
peaks in diagnostic samples was based on two criteria. The sus-
pected peak should fall within the valid size range supplied by 
the manufacturer and be at least three times higher than the 
height of the third largest peak in the background. In follow-up 
samples, peaks with identical sizes in diagnostic samples and 
with a height exceeding that of an adjacent peak were interpreted 
as positive. 
For NGS library preparation, DNA concentration was checked 
by using a Qubit 2.0 fluorometer (Thermo Fisher Scientific) and 
the Qubit dsDNA HS assay kit (Thermo Fisher Scientific), and 
adjusted to 10 ng/μL. The library was generated from 50 ng of 
DNA per sample using the LymphoTrack IGH assay kit. The kit 
uses single multiplex master mixes targeting the conserved site 
in the variable region and the joining region of IGH. For each 
run, positive and negative controls included in the kit were as-
sayed simultaneously. After PCR amplification, the libraries were 
purified by using the Agencourt AMPure XP system (Beckman 
Coulter, Brea, CA, USA). Eighteen samples from patient 1–7 were 
tested by using the Ion Torrent PGM. Emulsion PCR was con-
ducted by using the Ion OneTouch 400 template kit, and the 
enriched libraries were sequenced on the 318 chip with the Ion 
PGM Sequencing 400 kit (all from Thermo Fisher Scientific). Four 
samples from patient 8 were sequenced on the MiSeq System 
using the MiSeq Reagent Nano Kit v2 (Illumina) and the MiSeq 
Reagent Kit v2 (Illumina). Raw sequence data in FASTQ format 
were analyzed by using the Lymphotrack software package (In-
VivoScribe Technologies). The frequency of identical sequences 
in NGS was calculated by dividing the number of sequence reads 
by the total number of sequence reads in the sample. For inter-
pretation, we adopted previously reported criteria [12] and de-
termined a 5% frequency as the cut-off for a leukemic clone in 
initial diagnostic samples. The presence of MRD in follow-up sam-
ples was determined by the presence of identical sequences of 
leukemic clones in the initial samples, even if the frequency of 
clone was less than 5%. 
Patient demographics and the results of IGH clonality tests 
are summarized in Table 1. Total read counts ranged from 7,422 
to 518,728. Interpretable results were obtained with higher sen-
sitivity compared with fragment analysis, even in samples with 
relatively fewer reads (patients 3 and 7). Seven patients (patients 
1–7) had no molecular markers other than the clonal IGH rear-
rangement, whereas patient 8 was positive for t(9;22)(q34;q11.2); 
BCR-ABL1. All initial diagnostic samples were positive for IGH 
clonality by both fragment analysis and NGS. 
Two patients (patients 7 and 8) had a single monoclonal clone 
according to the sequences identified by NGS, while five pati-
ents (patients 2–6) had two different clones and one patient (pa-
tient 1) had three clones. The proportion of leukemic clones in 
the IGH repertoire varied among samples (median 51.4%; range 
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25.5–64.5%). Among 14 follow-up samples, excluding one in 
relapse, three were positive in both fragment analysis and NGS 
(median 15.4%; range 13.7–17.5%). In contrast, six follow-up 
samples were negative by fragment analysis but positive by NGS 
(median 2.6%; range 0.1–14.3%). The proportions decreased 
as chemotherapy progressed, and converted to negative in four 
patients at 30 days after initial diagnosis. 
Patient 8 was under long-term monitoring with real-time PCR 
for the BCR-ABL1 fusion transcript. He received an allogenic 
bone marrow transplantation after eight months of chemother-
apy. However, the disease relapsed one year after initial diagno-
sis and the patient died six months thereafter from pneumonia 
and systemic shock. At 10 months after initial diagnosis, which 
was just before full-blown relapse, BCR/ABL1 was negative but 
IGH NGS showed the presence of initial clones (Fig. 1). 
Clonal IGH rearrangement in B-ALL has an advantage as an 
MRD marker owing to its broad applicability and high positivity 
rate (84–95%) in all B-ALL cases [12, 13]. Because the con-
ventional method , fluorescence PCR-fragment analysis using a 
capillary electrophoresis sequencer, has a limitation of low sen-
sitivity (1–10%), other sensitive methods such as real-time PCR 
with patient-specific primers have been tested for IGH clonality 
detection in MRD monitoring [9]. However, the labor- and time-
consuming procedures of designing and validating patient-spe-
cific primers have been major hurdles of its widespread applica-
tion in clinical laboratories [12]. Moreover, there is a possibility 
of false-negative results because primers specifically designed 
for initial diagnostic clones can miss newly emerging clones with 
different genetic properties [12]. 
The sensitivity of NGS for detecting IGH clonality has been re-
ported at 0.001–0.00001% in recent studies using different plat-
forms [6, 12, 14]. In addition to fragment analysis, we detected 
six more positives by NGS in follow-up samples with a low pro-
portion of clonal leukemic cells. Four patients (patients 2, 3, 5, 
and 6) with discrepant results were followed up with a complete 
remission state until 30–59 months after diagnosis. However, in 
one relapsed patient with the BCR-ABL1 fusion, the MRD level 
detected by NGS was comparable to or even more sensitive than 
BCR-ABL1 detection with real-time PCR. An additional experi-
ment with six follow-up samples from six other B-ALL patients 
(data not shown) revealed a similar pattern: five samples showed 
concordant results (two positives and three negatives), and one 
sample showed a positive result in NGS and a negative result in 
fragment analysis. The clinical implication of these findings should 
be further validated in a study with a larger patient cohort.
Another advantage of NGS is that it can identify the number 
Fig. 1. Next-generation sequencing (NGS) results using MiSeq (Il-
lumina) for IGH clonality detection at diagnosis (A), follow-up (B, C), 
and full-blown relapse (D) in Patient 8. Each colored box represents 
the frequency of reads with an identical sequence. NGS showed a 
leukemic clone frequency of 57.7% (A) at initial diagnosis and of 
14.3% (B) at 30 days after diagnosis (white arrows). (C) A residual 
leukemic clone frequency of 2.8% was found by NGS at two months 
before full-blown relapse, although PCR fragment analysis for IGH 
clonality detection and real-time PCR for BCR-ABL1 transcript quan-
tification showed negative results. 
A
B
C
D
and DNA sequence of tumor clones within a sample. In this study, 
the numbers of clones at initial diagnosis ranged from one to 
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three among patients. Previous studies reported the possibility 
of multiple leukemic clones in each B-ALL sample because of 
ongoing clonal evolution [13]. Because of the small number of 
cases in this study, the clinical significance of the number and 
type of leukemic clones could not be analyzed. This should be 
explored in future studies involving a large and diverse patient 
series. 
In summary, we evaluated an NGS-based IGH clonality assay 
using initial and follow-up samples of B-ALL patients. Using pre-
designed primer set in library preparation kit and the provided 
software optimized for bioinformatics analysis, the experimental 
and bioinformatics analysis processes were streamlined. Fur-
thermore, compared with conventional fluorescence PCR-frag-
ment analysis, the NGS method was more sensitive in detecting 
positive follow-up samples. The prognostic impact of these low-
level MRD detected by NGS should be validated with more data 
and further investigation. Nevertheless, we suggest that this NGS 
assay can be applicable for MRD monitoring in B-ALL in clinical 
laboratories. 
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